DE602007009944D1 - Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon - Google Patents

Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon

Info

Publication number
DE602007009944D1
DE602007009944D1 DE602007009944T DE602007009944T DE602007009944D1 DE 602007009944 D1 DE602007009944 D1 DE 602007009944D1 DE 602007009944 T DE602007009944 T DE 602007009944T DE 602007009944 T DE602007009944 T DE 602007009944T DE 602007009944 D1 DE602007009944 D1 DE 602007009944D1
Authority
DE
Germany
Prior art keywords
diabetes
arntl2
gene
insulin
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009944T
Other languages
German (de)
English (en)
Inventor
Philip Avner
Ute Christine Rogner
Ming-Shiu Hung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of DE602007009944D1 publication Critical patent/DE602007009944D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
DE602007009944T 2006-02-27 2007-02-27 Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon Active DE602007009944D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77666206P 2006-02-27 2006-02-27
PCT/IB2007/001649 WO2007099461A2 (en) 2006-02-27 2007-02-27 Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes

Publications (1)

Publication Number Publication Date
DE602007009944D1 true DE602007009944D1 (de) 2010-12-02

Family

ID=38442622

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009944T Active DE602007009944D1 (de) 2006-02-27 2007-02-27 Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon

Country Status (7)

Country Link
US (2) US7960107B2 (enExample)
EP (1) EP1994174B1 (enExample)
JP (1) JP2009528030A (enExample)
AT (1) ATE485399T1 (enExample)
CA (1) CA2638825A1 (enExample)
DE (1) DE602007009944D1 (enExample)
WO (1) WO2007099461A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960107B2 (en) 2006-02-27 2011-06-14 Institut Pasteur Method of determining the susceptibility of a subject to developing insulin-dependent diabetes
CN109295210A (zh) * 2018-10-30 2019-02-01 深圳市万众基因转化医学研究院 一种人类2型糖尿病相关基因突变筛查的组合引物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3769465B2 (ja) * 2001-02-13 2006-04-26 独立行政法人科学技術振興機構 新規時計遺伝子Ｂｍａｌ２
WO2006019824A2 (en) * 2004-07-15 2006-02-23 Joslin Diabetes Center, Inc. Methods of treating diabetes
US7960107B2 (en) 2006-02-27 2011-06-14 Institut Pasteur Method of determining the susceptibility of a subject to developing insulin-dependent diabetes

Also Published As

Publication number Publication date
JP2009528030A (ja) 2009-08-06
US20070214510A1 (en) 2007-09-13
EP1994174B1 (en) 2010-10-20
US20090181915A1 (en) 2009-07-16
ATE485399T1 (de) 2010-11-15
CA2638825A1 (en) 2007-09-07
WO2007099461A2 (en) 2007-09-07
EP1994174A2 (en) 2008-11-26
HK1126251A1 (en) 2009-08-28
WO2007099461A3 (en) 2007-12-27
US7960107B2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
EA201000584A1 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
NO20073636L (no) Sammensetninger og metoder til a behandle mentale lidelser
ATE383870T1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
DE602007009944D1 (de) Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon
MA29397B1 (fr) Methode de traitement ou de prevention du diabete de type 2
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE546547T1 (de) Diagnose der chronischen abstossung
MX2009004792A (es) Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
ATE455577T1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von laptm4b
ATE393243T1 (de) Diagnostisches verfahren der mastozytose
WO2010079340A3 (en) Methods for identifying compounds modulating type-i transmebrane matrix metalloproteinase (mmp)
ATE549352T1 (de) Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms
ATE516813T1 (de) Verfahren und verbindungen zur behandlung von diabetes
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
WO2003103601A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren